Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 5 November 2024, 10:35 HKT/SGT
Share:
    

Source: Eisai
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"

TOKYO, Nov 5, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai Innovation,Inc. has been selected as a registered venture capital (Registered VC) of the Strengthening Program for Pharmaceutical Startup Ecosystem implemented by the Japan Agency for Medical Research and Development (AMED).

To address the shortage of large-scale funding necessary for new drug development, this program provides subsidies to pharmaceutical startups for development and commercialization. This support is contingent upon startups securing funding from AMED-registered venture capital firms, which specialize in drug development and offer hands-on business management and commercialization support.

The Eisai global network of affiliated companies (the “Eisai Group”) launched its venture investment business in May 2019, aiming to support the acceleration of drug discovery innovation and the establishment of an ecosystem platform in areas includingdementia. This involves supporting the discovery of innovative technologies and services by supporting venture businesses with such capabilities and exploring possible future collaborations with these businesses. Eisai Innovation, Inc. was established in the

U.S. in August 2019 as Eisai’s corporate venture capital subsidiary. It identifies opportunities for the Eisai Group to invest in venture businesses that align with Eisai’s goal of contributing to patients, focusing on cutting-edge drug discovery platforms, andnew modalities, as well as leading biotechnology in focus areas of neurology, oncology, and global health. The company also supports investment in drug discovery technologies in other areas, where significant future innovations are anticipated. As anAMED-registered VC, Eisai Innovation, Inc. aims to further contribute to strengthening the drug discovery venture ecosystem in Japan.

Eisai and Eisai Innovation, Inc. are committed to utilizing their participation in the Strengthening Program for PharmaceuticalStartup Ecosystem to accelerate flexible support of academia, drug discovery ventures, and IT ventures, to create innovative new medicines targeting diseases with high unmet medical needs., Eisai aims to effectively achieve social good in the form of relievinganxiety over health and reducing health disparities by creating solutions through an ecosystem in collaboration with other industries.

*Please refer to following web page for Eisai’s venture investment business
www.eisai.com/innovation/cvc/index.html https://www.eisaiinnovation.com/

MEDIA CONTACTS

Eisai Co., Ltd.
Public Relations Department
TEL : +81 (0)3-3817-5120

Eisai Innovation, Inc. https://www.eisaiinnovation.com/




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 29, 2025 08:01 HKT/SGT
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
July 25, 2025 12:31 HKT/SGT
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
July 23, 2025 09:07 HKT/SGT
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
July 22, 2025 10:56 HKT/SGT
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
July 16, 2025 13:50 HKT/SGT
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
July 14, 2025 09:20 HKT/SGT
"URECE" (Dotinurad) Launched in China as a treatment for Gout
July 8, 2025 08:31 HKT/SGT
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
June 2, 2025 16:46 HKT/SGT
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
May 28, 2025 16:45 HKT/SGT
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 21, 2025 14:00 HKT/SGT
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: